Search
Results: 3
Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Seerapani Gopaluni, Oliver Flossmann, Mark A Little, Paul O'Hara, Pirow Bekker, David Jayne, European Vasculitis Society
Dec 13, 2018
OBJECTIVE: The treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) aims to suppress disease activity and prevent subsequent disease flare. This study sought to explore the association of early...
Adult Age Factors Aged Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Female Glomerular Filtration Rate Humans Immunosuppressive Agents Kidney Failure Chronic Male Middle Aged Mortality Plasma Exchange Prognosis Proportional Hazards Models Recurrence Remission Induction Severity of Illness Index
Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS)
Michael Walsh, Peter A Merkel, Chen Au Peh, Wladimir Szpirt, Loïc Guillevin, Charles D Pusey, Janak De Zoysa, Natalie Ives, William F Clark, Karen Quillen, Jeffrey L Winters, Keith Wheatley, David Jayne, PEXIVAS Investigators
Mar 25, 2013